GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotron Ltd (OTCPK:BITRF) » Definitions » EV-to-EBITDA

Biotron (Biotron) EV-to-EBITDA

: -10.69 (As of Today)
View and export this data going back to 2012. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biotron's enterprise value is $40.63 Mil. Biotron's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.80 Mil. Therefore, Biotron's EV-to-EBITDA for today is -10.69.

The historical rank and industry rank for Biotron's EV-to-EBITDA or its related term are showing as below:

BITRF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.27   Med: 0   Max: 3.48
Current: -11.81

During the past 13 years, the highest EV-to-EBITDA of Biotron was 3.48. The lowest was -30.27. And the median was 0.00.

BITRF's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 9.16 vs BITRF: -11.81

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Biotron's stock price is $0.0585. Biotron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.003. Therefore, Biotron's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biotron EV-to-EBITDA Historical Data

The historical data trend for Biotron's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotron Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.16 -12.59 -9.15 -15.07 -5.66

Biotron Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -15.07 - -5.66 -

Competitive Comparison

For the Biotechnology subindustry, Biotron's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotron EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Biotron's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biotron's EV-to-EBITDA falls into.



Biotron EV-to-EBITDA Calculation

Biotron's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=40.633/-3.802
=-10.69

Biotron's current Enterprise Value is $40.63 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotron's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotron  (OTCPK:BITRF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biotron's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0585/-0.003
=At Loss

Biotron's share price for today is $0.0585.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.003.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biotron EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biotron's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotron (Biotron) Business Description

Traded in Other Exchanges
Address
56 Delhi Road, Suite 3.3, North Ryde, Sydney, NSW, AUS, 2113
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

Biotron (Biotron) Headlines

From GuruFocus

Biotron Drug Effective Against COVID-19 In Animals

By PRNewswire PRNewswire 11-25-2021